Treatment for colorectal cancer: impact on health-related quality of life

doi:10.1017/CBO9780511545856.008

8 - Treatment for colorectal cancer: impact on health-related quality of life

Published online by Cambridge University Press: 18 December 2009

Carol M. Moinpour Ph.D. and

Dawn Provenzale M.D., M.S.

Edited by

Joseph Lipscomb ,

Carolyn C. Gotay and

Claire Snyder

Show author details

Carol M. Moinpour Ph.D.: Affiliation:
Fred Hutchinson Cancer Research Center, Seattle, WA
Dawn Provenzale M.D., M.S.: Affiliation:
Professor of Medicine and Director GI Outcomes Research Duke University Medical Center, Durham, NC
Joseph Lipscomb: Affiliation:
National Cancer Institute, Bethesda, Maryland
Carolyn C. Gotay: Affiliation:
Cancer Research Center, Hawaii
Claire Snyder: Affiliation:
National Cancer Institute, Bethesda, Maryland

Book contents

Get access

Summary

Introduction

Colorectal cancer (CRC) is the second leading cause of cancer death in the US each year. It is estimated that in 2002 there were 148 300 new cases and 56 600 deaths from CRC. Direct evidence from randomized trials and indirect evidence from case-control and cohort studies– suggest that screening affects 5-year survival. Specifically, screening can identify pre-cancerous lesions and prevent development of CRC or identify CRC in earlier stages (I and II) when it can be treated more effectively. The relative 5-year survival rates for early-stage disease (I and II) and advanced disease have been estimated at 65%–90% and 9%, respectively. Because most patients diagnosed with CRC have not undergone screening, most CRCs are diagnosed after local or regional spread, and nearly half of all patients so diagnosed will die from it.

Treatment for CRC is based on the stage and location of disease and includes surgery, chemotherapy, and/or radiation therapy. These modalities may be associated with substantial toxicity, including hair loss, profound nausea and vomiting, and fecal incontinence. Furthermore, therapy for CRC may result in the formation of a permanent or temporary stoma. All of these treatments may have side effects that have an important effect on health-related quality of life (HRQOL).

Treatment for colon cancer includes surgical resection for stage I and II disease, and surgery plus chemotherapy for stage III and selected patients with stage IV disease. Palliative care is provided to patients with unresectable disease.

Type: Chapter
Information: Outcomes Assessment in Cancer
Measures, Methods and Applications
, pp. 178 - 200

DOI: https://doi.org/10.1017/CBO9780511545856.008 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

National Cancer Institute. Colorectal Screening. http://www.cancer.gov/cancerinfo/pdq/screening/colorectal/healthprofessional. Last accessed September 11, 2004

Mandel, J. S., Bond, J. H., Church, T. R.et al. (1993). Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control StudyNew England Journal of Medicine 328:1365–71CrossRef Google Scholar PubMed

Selby, J. V., Friedman, G. D., Quesenberry, C. P. Jr.et al. (1992). A case-control study of screening sigmoidoscopy and mortality from colorectal cancerNew England Journal of Medicine 326:653–7CrossRef Google Scholar PubMed

Newcomb, P. A., Norfleet, R. G., Storer, B. E.et al. (1992). Screening sigmoidoscopy and colorectal cancer mortalityJournal of the National Cancer Institute 84:1572–5CrossRef Google Scholar PubMed

Muller, A. D., Sonnenberg, A. (1995). Protection by endoscopy against death from colorectal cancerArchives of Internal Medicine 155:1741–8CrossRef Google Scholar PubMed

National Cancer Institute. Colon cancer treatment. http://www.cancer.gov/cancerinfo/pdq/treatment/colon. Last accessed September 11, 2004

Ries, L. A. G., Eisner, M. P., Kosary, C. L. et al. (eds). (2002). SEER Cancer Statistics Review, 1973–1999. Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/csr/1973_1999. Accessed September 11, 2004

Aaronson, N. K., Ahmedzai, S., Bergman, B.et al. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncologyJournal of the National Cancer Institute 85:365–76CrossRef Google Scholar

Kaasa, S., Mastekaasa, A., Stokke, I.et al. (1988). Validation of a quality of life questionnaire for use in clinical trials for treatment of patients with inoperable lung cancerEuropean Journal of Cancer and Clinical Oncology 24:691–701CrossRef Google Scholar PubMed

Glimelius, B., Hoffman, K., Olafsdottir, M.et al. (1989). Quality of life during cytostatic therapy for advanced symptomatic colorectal carcinoma: a randomized comparison of two regimensEuropean Journal of Cancer and Clinical Oncology 25:829–35CrossRef Google Scholar PubMed

Adang, E. M., Engel, G. L., Konsten, J.et al. (1993). Quality of life after dynamic graciloplasty for fecal incontinence: first resultsThoracic Surgery 8:122–4Google Scholar

Renner, K., Rosen, H. R., Novi, G.et al. (1999). Quality of life after surgery for rectal cancer: do we still need a permanent colostomy?Diseases of the Colon and Rectum 42:1160–7CrossRef Google Scholar

Björvell, H., Hylander, B. (1989). Functional status and personality in patients on chronic dialysisJournal of Internal Medicine 226:319–24CrossRef Google Scholar PubMed

Forsberg, C., Bjorvell, H., Cedermark, B. (1996). Well-being and its relation to coping ability in patients with colo-rectal and gastric cancer before and after surgeryScandinavian Journal of Caring Science 10:35–44CrossRef Google Scholar PubMed

Schipper, H., Clinch, J., McMurray, A.et al. (1984). Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validationJournal of Clinical Oncology 2:472–83CrossRef Google Scholar PubMed

Morrow, G. R., Lindke, J., Black, P. (1992). Measurement of quality of life in patients: psychometric analyses of the Functional Living Index-Cancer (FLIC)Quality of Life Research 1:287–96CrossRef Google Scholar

Haes, J. C. J. M., Oostrom, M. A., Welvaart, K. (1986). The effect of radical and conserving surgery on the quality of life of early breast cancer patients.European Journal of Surgical Oncology 12:337–42Google Scholar PubMed

de Haes, J. C. J. M., Raatgever, J. W., van der Burg, M. E. L. et al. (1987). Evaluation of the quality of life of patients with advanced ovarian cancer treated with combination chemotherapy. In The Quality of Life of Cancer Patients, ed. N. K. Aaronson, J. Beckman, pp. 215–26. New York: Raven Press

Haes, J. C. J. M., Knippenberg, F. C. E., Neijt, J. P. (1990). Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom ChecklistBritish Journal of Cancer 62:1034–38CrossRef Google Scholar PubMed

Haes, J. C. J. M., Olschewski, M. (1998). Quality of life assessment in a cross-cultural context: use of the Rotterdam Symptom Checklist in a multinational randomised trial comparing CMF and Zoladex (Goserlin) treatment in early breast cancerAnnals of Oncology 9:745–50CrossRef Google Scholar

Spitzer, W. O., Dobson, A. J., Hall, J.et al. (1983). Measuring the quality of life of cancer patients. A concise QL- Index for use by physiciansJournal of Chronic Disease 34:585–97CrossRef Google Scholar

EuroQoL Group (1990). EuroQoL — a new facility for the measurement of health-related quality of lifeHealth Policy 16:199–208CrossRef

Kind, P. (1996). The EuroQoL instrument: an index of health-related quality of life. In Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edn), ed. B. Spilker, pp. 191–201. Philadelphia, PA: Lippincott-Raven

Zigmund, A. S., Snaith, R. P. (1983). The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica 67:361–70CrossRef Google Scholar

Hunt, S. M., McEwen, J., McKenna, S. P. (1986). Measuring Health Status. London: Croom Helm

Hunt, S. M., McKenna, S. P. (1991). The Nottingham Health Profile User's Manual. Manchester: Galen Research and Consultancy

McEwen, J., McKenna, S. P. (1996). Nottingham Health Profile. In Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edition), ed. B. Spilker, pp. 281–86. Philadelphia, PA: Lippincott-Raven

Lorr, M., McNair, D. M. (1982). Profile of Mood States: Bi-polar Form. San Diego: Educational and Industrial Testing Service

Shacham, S. (1983). A shortened version of the Profile of Mood StatesJournal of Personality Assessment 47:305–6CrossRef Google Scholar PubMed

Bergner, M., Bobbitt, R. A., Carter, W. B.et al. (1981). The Sickness Impact Profile: development and final revision of a health status measureMedical Care 19:787–805CrossRef Google Scholar PubMed

Damiano, A. M. (1996). The Sickness Impact Profile. In Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edition), ed. B. Spilker, pp. 347–54. Philadelphia, PA: Lippincott-Raven

Erickson, this volume, Chapter 3

Fayers, P., Aaronson, N., Bjordal, K. et al., on behalf of the EORTC Quality of Life Group. (2001). EORTC QLQ-C30 Scoring Manual (3rd Edition). Brussels: EORTC

Fayers, P., Weeden, S., Curran, D. (1998). EORTC QLQ-C30 Reference Values. Brussels: EORTC Study Group on Quality of Life

Sprangers, M. A., Cull, A., Bjordal, K.et al., for the EORTC Study Group on Quality of Life (1993). The European Organization for Research and Treatment of Cancer approach to quality of life assessment: Guidelines for developing modulesQuality of Life Research 2:287–95CrossRef Google Scholar

Sprangers, M. A. G. (1999). Quality-of-life assessment in colorectal cancer patients: evaluation of cancer therapiesSeminars in Oncology 26:691–6Google Scholar PubMed

Aaronson, N. K., Cull, A. M., Kaasa, S. et al. (1996). The European Organization for Research and Treatment of Cancer (EORTC) Modular Approach to Quality of Life Assessment in Oncology: An update. In Quality of Life and Pharmacoeconomics in Clinical Trials (2nd Edition), ed. B. Spilker, pp. 179–89. Philadelphia, PA: Lippincott-Raven

Sprangers, M. A. G., te Velde, A.,Aaronson, N. K. on behalf of the European Organization for Research and Treatment of Cancer Study Group on Quality of Life (1999). The construction of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38)European Journal of Cancer 35:238–47CrossRef Google Scholar

Sailer, M., Debus, E. S., Fuchs, K.-H. (2000). How useful is the EORTC QLQ-CR38 in the pre- and post-operative evaluation of patients with rectal cancer?Quality of Life Research Newsletter 25:13–14Google Scholar

Cella, D. F., Tulsky, D. S., Gray, G.et al. (1993). The Functional Assessment of Cancer Therapy scale: development and validation of the general measureJournal of Clinical Oncology 11:570–9CrossRef Google Scholar PubMed

Cella, D. (1997). FACIT Manual. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Version 4. Evanston, IL: Center on Outcomes, Research and Education (CORE)

Ward, W. L., Hahn, E. A., Mo, F.et al. (1999). Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrumentQuality of Life Research 8:181–95CrossRef Google Scholar PubMed

Courneya, K. S., Friedenreich, C. M. (1997). Relationship between exercise pattern across the cancer experience and current quality of life in colorectal cancer survivorsJournal of Alternative and Complementary Medicine 3:215–26CrossRef Google Scholar PubMed

Allal, A. S., Bieri, S., Peloni, A.et al. (2002). Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: feasibility, oncologic results and quality of life outcomesBritish Journal of Cancer 82:1131–7CrossRef Google Scholar

Cronbach, L. J. (1951). Coefficient alpha and the internal structure of testsPsychometrika 16:297–334CrossRef Google Scholar

Borras, J. M., Sanchez-Hernandez, A., Navarro, M.et al. (2001). Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trialBritish Medical Journal 322:1–5CrossRef Google Scholar PubMed

Bernhard, J., Hürny, C., Maibach, R., Herrmann, R.et al., for the Swiss Group for Clinical Cancer Research (SAKK). (1999). Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapyAnnals of Oncology 10:775–82CrossRef Google Scholar PubMed

Ulander, K., Jeppsson, B., Grahn, G. (1997). Quality of life and independence in activities of daily living preoperatively and at follow-up in patients with colorectal cancerSupportive Care in Cancer 5:402–9CrossRef Google Scholar PubMed

Whynes, D. K., Neilson, A. R. (1997). Symptoms before and after surgery for colorectal cancerQuality of Life Research 6:61–6CrossRef Google Scholar PubMed

Barsevick, A. M., Pasacreta, J., Orsi, A. (1995). Psychological distress and functional dependence in colorectal cancer patientsCancer Practice 3:105–10Google Scholar PubMed

Padilla, G. V., Grant, M. M., Lipsett, J.et al. (1992). Health quality of life and colorectal cancerCancer 70:1450–63.0.CO;2-E>CrossRef Google Scholar PubMed

Scieszka, M., Zielinski, M., Machalski, M.et al. (2000). Quality of life in cancer patients treated by chemotherapyNeoplasma 47:396–9Google Scholar PubMed

Anthony, T., Jones, C., Antoine, J.et al. (2001). The effect of treatment for colorectal cancer on long-term health-related quality of lifeAnnals of Surgical Oncology 8:44–9CrossRef Google Scholar PubMed

McHorney, C. A., Ware, J. E. Jr., Raczek, A. E. (1993). The MOS 36-item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructsMedical Care 31:247–63CrossRef Google Scholar PubMed

Langius, A., Björvell, H., Antonovsky, A. (1992). The Sense of Coherence concept and its relation to personality traits in Swedish samplesScandinavian Journal of Caring Science 6:165–71CrossRef Google Scholar PubMed

Antonovsky, A. (1987). Unraveling the Mystery of Health: How People Manage Stress and Stay Well. San Francisco, CA: Jossey-Bass Publishers

Garufi, C., Brienza, S., Pugliese, P.et al. (2000). Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patientsAnticancer Drugs 11:495–501CrossRef Google Scholar PubMed

Garufi, C., Dogliotti, L., D'Attino, R. M.et al. (2001). Irinotecan and chronomodulated infusion of 5-fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma: a phase I studyCancer 91:712–203.0.CO;2-4>CrossRef Google Scholar PubMed

Hauns, B., Häring, B., Köhler, S.et al. (2001). Phase II study of combined 5 fluorouracil/Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancerPhytotherapy Research 15:34–83.0.CO;2-2>CrossRef Google Scholar PubMed

Henry, B., Becouarn, Y., Aussage, P. (1999). Clinical benefits of stabilization with second line chemotherapy in patients with metastatic colorectal cancerOncology Hematology 32:145–54Google Scholar

Fordy, C., Glover, C., Davies, M. M.et al. (1998). Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastasesBritish Journal of Cancer 78:1058–60CrossRef Google Scholar PubMed

Cunningham, D., Zalcberg, J. R., Rath, U.et al. (1996). Final results of a randomised trial comparing ‘Tomudex’ (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. “Tomudex” Colorectal Cancer Study GroupAnnals of Oncology 7:961–5CrossRef Google Scholar PubMed

Cunningham, D., Glimelius, B. on behalf of the V301 Study Group. (1999). A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study GroupSeminars in Oncology 26:6–12Google Scholar PubMed

Gramont, A., Figer, A., Seymour, M.et al. (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerJournal of Clinical Oncology 18:2938–47CrossRef Google Scholar PubMed

Douillard, J. Y., Cunningham, D., Roth, A. D.et al. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialLancet 355:1041–7CrossRef Google Scholar PubMed

Hill, M., Norman, A., Cunningham, D.et al. (1995). Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancerJournal of Clinical Oncology 13:2317–23CrossRef Google Scholar PubMed

Ross, P., Norman, A., Cunningham, D.et al. (1997). A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancerAnnals of Oncology 8:995–1001CrossRef Google Scholar PubMed

Rougier, P., Cutsem, E., Bajetta, E.et al. (1998). Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerLancet 352:1407–12CrossRef Google Scholar PubMed

Saltz, L. B., Cox, J. V., Blanke, C.et al. (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study GroupNew England Journal of Medicine 343:905–14CrossRef Google Scholar PubMed

Cutsem, E., Blijham, G. H. on behalf of the V302 Study Group. (1999). Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracilSeminars in Oncology 26:13–20Google Scholar PubMed

Norum, J., Vonen, B., Olsen, J. A.et al. (1997). Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma: a cost-effectiveness analysisAnnals of Oncology 8:65–70CrossRef Google Scholar

Allen-Mersh, T. G., Earlam, S., Fordy, C.et al. (1994). Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastasesLancet 344:1255–60CrossRef Google Scholar PubMed

Allen-Mersh, T. G., Glover, C., Fordy, C.et al. (2000). Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastasesEuropean Journal of Surgical Oncology 26:468–73CrossRef Google Scholar PubMed

Cocconi, G., Cunningham, D., Cutsem, E.et al. (1998). Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study GroupJournal of Clinical Oncology 16:2943–52CrossRef Google Scholar PubMed

Earlam, S., Glover, C., Davies, M.et al. (1997). Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patientsJournal of Clinical Oncology 15:2022–9CrossRef Google Scholar PubMed

Seymour, M. T., Slevin, M. L., Kerr, D. J.et al. (1996). Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research CouncilJournal of Clinical Oncology 14:2280–8CrossRef Google Scholar PubMed

Sobrero, A., Zaniboni, A., Frassineti, G. L.et al. (2000). Schedule specific biochemical modulations of 5-fluorouracil in advanced colorectal cancer: A randomized study. GISCAD, IOR and collaborating centersAnnals of Oncology 11:1413–20CrossRef Google Scholar

Caudry, M., Bonnel, C., Floquet, A.et al. (1995). A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinomaAmerican Journal of Clinical Oncology 18:118–25CrossRef Google Scholar PubMed

Loprinizi, C. L., Juross, S. A., O'Fallon, J. R.et al. (1994). Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancerJournal of Clinical Oncology 12:1121–5CrossRef Google Scholar

Smyth, J. F., Hardcastle, J. D., Denton, G.et al. (1995). Two phase III trials of tauromustine (TCNU) in advanced colorectal cancerAnnals of Oncology 6:948–9CrossRef Google Scholar

Laufman, L. R., Bukowski, R. M., Collier, M. A.et al. (1993). A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancerJournal of Clinical Oncology 11:1888–93CrossRef Google Scholar PubMed

Scheithauer, W., Rosen, H., Kornek, G.-V.et al. (1993). Randomized comparison of combination 4 chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancerBritish Medical Journal 306:752–5CrossRef Google Scholar

Sullivan, B. A., McKinnis, R., Laufman, L. R. (1995). Quality of life in patients with metastatic colorectal cancer receiving chemotherapy: a randomized, double-blind trial comparing 5-FU versus 5-FU with leucovorinPharmacotherapy 15:600–7CrossRef Google Scholar PubMed

Glimelius, B., Hoffman, K., Graf, W.et al. (1994). Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancerCancer 73:556–623.0.CO;2-8>CrossRef Google Scholar PubMed

Leichman, C. G., Fleming, T. R., Muggia, F. M.et al. (1995). Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group studyJournal of Clinical Oncology 13:1303–11CrossRef Google Scholar PubMed

Moinpour, C. M., Triplett, J. S., McKnight, B.et al. (2000). Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trialPsycho-Oncology 9:340–543.0.CO;2-F>CrossRef Google Scholar

Moinpour, C. M., Savage, M., Hayden, K. A. et al. (1995). Quality of Life Assessment in Cancer Clinical Trials. In Quality of Life in Behavioral Medicine Research, ed. J. E. Dimsdale, A. Braun, pp. 79–95. Hillsdale, NJ: Lawrence Erlbaum Associates

Feeny, D., Furlong, W., Boyle, M.et al. (1995). Multi-attribute health status classification systems: Health Utilities IndexPharmacoeconomics 7:490–502CrossRef Google Scholar PubMed

Tobin, E. (2001). Report on Focus Group Research. Conducted for NCI's COMWG with cancer patients and survivors by Cancer Care Strategies. September, 2001. Completed under contract to the National Cancer Institute by E. Tobin

Zebrack, Cella, this volume, Chapter 11

Bernhard, J., Cella, D. F., Coates, A. S.et al. (1998). Missing quality of life data in cancer clinical trials: serious problems and challengesStatistics in Medicine 17:517–323.0.CO;2-S>CrossRef Google Scholar PubMed

Hogan, J. W., Laird, N. M. (1997). Mixture models for the joint distribution of repeated measures and event timesStatistics in Medicine 16:239–573.0.CO;2-X>CrossRef Google Scholar PubMed

Fairclough, this volume, Chapter 17

Sprangers, M. A. G., Taal, B. G., Aaronson, N. K.et al. (1995). Quality of life in colorectal cancer. Stoma vs. nonstoma patientsDiseases of the Colon and Rectum 38:361–9CrossRef Google Scholar PubMed

Camilleri-Brennan, J., Steele, R. J. C. (1998). Quality of life after treatment for rectal cancerBritish Journal of Surgery 85:1036–43CrossRef Google Scholar PubMed

Wils, J., Sahmoud, T., Sobrero, A.et al. (1998). Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCGTumori 84:335–47CrossRef Google Scholar PubMed

Sobrero, A., Belvedere, O., Ramello, M.et al. (2001). Endpoints of medical treatment of colorectal cancerTumori 87(Suppl. 1):S63–4Google Scholar PubMed

Allen, M., Cunningham, D., Schmitt, C. (1998). The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studiesAnti-Cancer Drugs 9:783–90CrossRef Google Scholar PubMed

Cull, A., Groenvold, M., on behalf of the EORTC Quality of Life Study Group. (1998). EORTC Quality of Life Study Group Translation Procedure. ISBN: 2-930064-15–3. Brussels: EORTC

Beck, A. T., Steer, R. A. (1987). Beck Depression Inventory (BDI) Manual. San Antonio: Harcourt Brace Jovanovich

Benoliel, J. Q., McCorkle, R., Young, K. (1983). The development of a social dependency scaleResearch in Nursing and Health 3:3–10CrossRef Google Scholar

McCorkle, R. M., Benoliel, J. Q., Donaldson, G.et al. (1989). A randomized clinical trial of home nursing care for lung cancer patientsCancer 57:358–64Google Scholar

Priestman, T., Baum, M. (1976). Evaluation of quality of life in patients receiving treatment for advanced breast cancerLancet 24:899–900CrossRef Google Scholar

Coates, A., Gebski, V., Bishop, J. F.et al. (1987). Improving the quality of life during chemotherapy for advanced breast cancerNew England Journal of Medicine 317:1633–7CrossRef Google Scholar PubMed

Ware, J. E. Jr., Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMedical Care 30:473–83CrossRef Google Scholar PubMed

McHorney, C. A., Ware, J. E. Jr., Lu, J. F. R., Sherbourne, C. D. (1994). The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groupsMedical Care 32:40–66CrossRef Google Scholar PubMed

Ware, Jr., J. E., Snow, K. K., Kosinski, M. et al. (1993). SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute